Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKAZAR
NCT06765109Phase 3Recruiting
- Sponsor
- Nuvalent
- Start
- Jul 2025
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 29
01
Overview
A Phase 3 trial of neladalkib in non-small cell lung cancer (NSCLC), sponsored by Nuvalent. Started Jul 2025; status: recruiting.
02
Drugs
neladalkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06765109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06765109.